Cerebral neuroblastoma

Summary

Cerebral neuroblastoma (MONDO:0002900) is a disease. A subtype of cerebral hemisphere cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cerebral neuroblastoma
Mondo ID	MONDO:0002900
DOID	DOID:0080905, DOID:4164
NCIT	C4826
SNOMED CT	281560004
UMLS	C0559458
MedGen	107851
GARD	0023294
Anatomy (UBERON)	UBERON:0001893
Is cancer (heuristic)	no

Also known as: cerebral hemispheric neuroblastoma · cerebral neuroblastoma, PNET · neuroblastoma of cerebral hemispheres · neuroblastoma of telencephalon · neuroblastoma of the cerebral hemispheres · neuroblastoma of the cerebrum · telencephalon neuroblastoma

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › supratentorial cancer › cerebral hemisphere cancer › cerebral neuroblastoma

Related subtypes (9): corpus callosum oligodendroglioma, parietal lobe cancer, temporal lobe cancer, cerebral lymphoma, cerebral meningioma, childhood cerebral astrocytoma, cerebral primitive neuroectodermal tumor, pediatric cerebral ependymoblastoma, frontal lobe ependymal tumor

Subtypes (1): cns neuroblastoma with FOXR2 activation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.